

Effect of Shenfu Injection on Myocardial Injury After Primary PCI for STEMI:

The RESTORE Trial

Brief title: Shenfu Injection for Cardioprotection

Xiao Wang, MD^{1,2}; Zeyuan Fan, MD³; Jianjun Jiang, MD⁴; Jincheng Guo, MD⁵;
Zhifang Wang, MD⁶; Likun Ma, MD⁷; Ruili He, MD⁸; Guohai Su, MD⁹; Hongtao Liu,
MD¹⁰, Delu Yin, MD¹¹; Guoan Zhao, MD¹²; Yingying Guo, MD²; Meixia Shang, MD¹³;
Xinliang Ma, MD, PhD¹⁴; Shaoping Nie, MD, PhD²

¹Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

²Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

³Department of Cardiovascular Diseases, Civil Aviation General Hospital, Civil Aviation Clinical Medical College of Peking University, Beijing, China

⁴Department of Cardiology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, Zhejiang, China

⁵Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, Beijing, China

⁶Department of Cardiology, Xinxiang Central Hospital, The Fourth Clinical College of
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Xinxiang Medical University, Xinxiang, Henan, China

⁷Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

⁸Department of Cardiology, Huaihe Hospital of Henan University, Kaifeng, China

⁹Department of Cardiology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

¹⁰Department of Cardiology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China

¹¹Department of Cardiology, The First Hospital of Lianyungang, Xuzhou Medical University, Lianyungang, China

¹²Department of Cardiology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China

¹³Department of Biostatistics, Peking University First Hospital, Beijing, China

¹⁴Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA

Address for correspondence:

Shaoping Nie, MD, FACC, FESC, FSCAI

Center for Coronary Artery Disease, Division of Cardiology

Beijing Anzhen Hospital, Capital Medical University

2 Anzhen Road, Chaoyang District

Beijing 100029, China

Tel: 86-10-84005256

Fax: 86-10-64439768

E-mail: spnie@ccmu.edu.cn

Total word count: 8060 words

1 **Effect of Shenfu Injection on Myocardial Injury After Primary PCI for STEMI:**

2 **The RESTORE Trial**

3

4 **Brief title:** Shenfu Injection for Cardioprotection

5

6 **ABSTRACT**

7 **BACKGROUND:** Shenfu injection, as a traditional Chinese medicine, can alleviate
8 reperfusion injury after ST-segment elevation myocardial infarction (STEMI) through
9 multiple pharmacologic effects. This trial aimed to evaluate the effect of Shenfu
10 injection on myocardial injury in STEMI patients undergoing primary percutaneous
11 coronary intervention (PCI).

12 **METHODS:** This was a multicenter, randomized, double-blind, parallel-group,
13 placebo-controlled trial. First-time anterior STEMI patients undergoing primary PCI
14 within 12 hours of symptom onset due to a proximal or mid left anterior descending
15 artery occlusion were randomized 1:1 to receive either intravenous Shenfu injection
16 or placebo before reperfusion and followed by once a day until 5 days after primary
17 PCI. The primary endpoint was infarct size by cardiac magnetic resonance (CMR) at
18 5 days after randomization.

19 **RESULTS:** A total of 295 patients were randomized with evaluable CMR in 273
20 patients. Infarct size ($37.4\pm 14.1\%$ vs $37.5\pm 14.5\%$; effect size -0.04% , 95%
21 confidence interval: $-3.45, 3.37$; $P=0.982$) did not differ between the Shenfu injection

1 and placebo groups. This was true for other CMR parameters. The area under curve
2 for creatine kinase-myocardial band did not differ between groups. The incidences of
3 thrombolysis in myocardial infarction (TIMI) flow grade 3 (94.8% vs 97.1%, P=0.324),
4 TIMI myocardial perfusion grade 3 (91.7% vs 92.1%, P=0.914), and ST-segment
5 resolution $\geq 70\%$ (25.4% vs 26.1%, P=0.906), were also similar between groups.
6 Adverse events were evenly distributed across groups.

7 **CONCLUSIONS:** For patients with anterior STEMI undergoing primary PCI,
8 administration of Shenfu injection was safe but did not reduce infarct size by CMR.

9 **REGISTRATION:** URL: <https://www.clinicaltrials.gov>; Unique identifier:
10 NCT04493840.

11 **Key Words:** cardiac magnetic resonance imaging, myocardial infarction, myocardial
12 injury, primary percutaneous coronary intervention, Shenfu injection

1 **Clinical Perspective**

2 **What Is New?**

- 3 • Among 295 anterior ST-segment elevation myocardial infarction patients
4 randomized to intravenous Shenfu injection or placebo, the primary analysis
5 demonstrated that the infarct size revealed by cardiac magnetic resonance was
6 37.4 % in the Shenfu injection group and 37.5% in the placebo group, a
7 difference that was not statistically significant.
- 8 • For patients with anterior ST-segment elevation myocardial infarction patients
9 undergoing primary percutaneous coronary intervention, administration of
10 Shenfu injection was safe and well tolerated.

11 **What Are the Clinical Implications?**

- 12 • Cardiovascular clinicians need to realize that successful cardioprotective
13 therapies may require synergistic multitarget approaches.
- 14 • Future clinical trials are required to investigate the use of additive
15 cardioprotective strategies in patients with large infarcts or severe hemodynamic
16 alterations (eg. concomitant heart failure or cardiogenic shock).

17

1 **Nonstandard Abbreviations and Acronyms**

- 2 AE adverse event
- 3 CMR cardiac magnetic resonance
- 4 LAD left anterior descending
- 5 LV left ventricular
- 6 MACCE major adverse cardiovascular and cerebrovascular event
- 7 PCI percutaneous coronary intervention
- 8 SAE serious adverse event
- 9 STEMI ST-segment elevation myocardial infarction
- 10 TIMI thrombolysis in myocardial infarction

1 INTRODUCTION

2 Despite advances in reperfusion strategies and concomitant antithrombotic therapy,
3 the morbidity and mortality of acute ST-segment elevation myocardial infarction
4 (STEMI) remain substantial¹. Reperfusion therapy rescues the ischemic myocardium
5 but paradoxically induces myocardial injury²⁻⁴. Multiple cardioprotective therapies
6 have been proposed to reduce infarct size but showed inconsistent clinical efficacy⁵⁻
7 ¹¹. Specifically, multifaceted pathophysiological factors (endothelial dysfunction,
8 microvascular obstruction, calcium overload, oxidative stress, inflammation, and
9 mitochondrial dysfunction) were involved in the process of reperfusion injury^{2, 12-14}.
10 As such, the most promising approach to cardioprotection may be to combine
11 multitarget therapy with synergistic cardioprotective effect.

12 Shenfu injection, a component-based Chinese medicine with “Yang”-restoring
13 and “Qi”-tonifying property, is exacted from ginseng (*Panax*; family: Araliaceae) and
14 aconite (*Radix aconiti lateralis preparata*, *Aconitum carmichaeli* Debx; family:
15 Ranunculaceae)^{15, 16} with ginsenosides and aconite alkaloids as the main active
16 ingredients, containing 1 mg/ml *Panax ginseng* C.A. Mey and 2 mg/ml *Aconitum*
17 *Carmichaeli* Debeaux^{17, 18}. Shenfu injection exerts synergistic cardioprotective effect
18 by forming a complex pharmacologic network directed to distinct signaling pathways
19 within the cardiomyocyte, and it could improve the efficacy by the combination of
20 multi-components and multitargets^{17, 19}. In our pilot study, we demonstrated the
21 feasibility and safety of Shenfu injection after primary percutaneous coronary
22 intervention (PCI) for STEMI²⁰. Consequently, we designed the RESTORE

1 (Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury) trial
2 powered to assess the effects of Shenfu injection on myocardial infarct size as
3 determined by cardiac magnetic resonance (CMR) imaging in patients with STEMI
4 undergoing primary PCI.

5 **METHODS**

6 **Study design**

7 The RESTORE trial was an investigator-initiated, multicenter, randomized, double-
8 blind, parallel-group, placebo-controlled trial to evaluate the effect of Shenfu injection
9 compared with placebo on myocardial injury in patients with a first-time anterior
10 STEMI following successful primary PCI, conducted in accordance with the Helsinki
11 Declaration. This trial was approved by the Institutional Review Board of Beijing
12 Anzhen Hospital, Capital Medical University (2019013) and the institutional review
13 committee at each clinical center. All participants provided written informed consent
14 prior to randomization. This trial was registered at ClinicalTrials.gov (NCT04493840).

15 A more detailed protocol has been previously reported²¹. Briefly, patients aged
16 18-75 years, with first-time anterior STEMI undergoing primary PCI with the time
17 from onset of ischemic symptom to the time of initial balloon inflation \leq 12 hours
18 were eligible for randomization. Further angiographic criteria included the presence
19 of left anterior descending branch (LAD) occlusion in proximal or middle segment
20 with pre-PCI thrombolysis in myocardial infarction (TIMI) flow 0 or 1. Key exclusion
21 criteria were cardiogenic shock, serious heart failure, malignant ventricular
22 arrhythmia, mechanical complications, prior myocardial infarction, PCI or bypass

1 surgery, and known contraindication for CMR imaging. Full eligibility and exclusion
2 criteria are shown in Table S1. The participants were enrolled between July 2020 and
3 May 2023 in eleven regional cardiac centers in China.

4 **Randomization and blindness**

5 Patients were randomly assigned 1:1 to either Shenfu injection or matching placebo
6 by using an Interactive Web Response System (IWRS) before primary PCI and the
7 randomization sequence was performed in blocks of 4. The IWRS was maintained
8 by a third-party of the Institute of Clinical Research, Peking University. The
9 randomization number assigned by IWRS automatically corresponded with a unique
10 medication number of research drugs (Shenfu injection or placebo).

11 The Shenfu injection and placebo were provided by the collaborator, China
12 Resources Sanjiu Medical & Pharmaceutical Co, Ltd, and packaged based on the
13 randomization allocation list and the blinded principle. The study drug Shenfu
14 injection was a colored transparent liquid, while the placebo 5% glucose injection
15 was a colorless transparent liquid. For reducing the bias, a disposable lucifugal
16 infusion bag and apparatus was used during the infusion to efficiently cover the
17 study drug and matched placebo. To maintain the double-blind design, only the
18 designated unblinded medical professional knows the group information. The
19 injection was prepared by the medical professional according to the dosage of the
20 study drug in a separate room. All the medical professionals followed the blind and
21 mask standard operating procedure and were required to sign a confidentiality
22 agreement. The study investigator (doctors), subjects, data managers, statisticians,

1 and clinical research associate were all blinded to the treatment group allocation.

2 **Study treatment**

3 After randomization, each patient who fulfilled with all the clinical inclusion/exclusion
4 criteria and signed the informed consent forms received Shenfu injection (80ml
5 Shenfu injection + 70ml 5% glucose injection) or matched placebo (150ml 5%
6 glucose injection). The rationale behind the route of administration, timing and
7 dosage of study medication has been previous published^{20,21}. Intravenous infusion
8 was started no more than 60 minutes before the anticipated PCI and continued for at
9 least 30 minutes after restoration of blood flow in the culprit vessel, followed by
10 infusion once a day and maintained for 5 days.

11 All patients received the standard treatments of STEMI in terms of reperfusion
12 therapy and medical therapies according to contemporary practice guidelines and
13 local standard of care. Other Chinese Medicine injections and oral medicines were
14 not allowed to be used.

15 **Clinical follow-up**

16 All randomized subjects underwent follow-up by telephone interviews or outpatient
17 visit (preferred) at 30 days after randomization. The follow-up data including vital
18 signs, laboratory tests, echocardiography, major adverse cardiovascular and
19 cerebrovascular events (MACCE), questionnaire of quality of life, adverse event
20 (AE), serious adverse event (SAE) and concomitant medications were collected.

21 **Endpoints**

22 The primary endpoint was infarct size as a percentage of the total left ventricular (LV)

1 mass as assessed by CMR at 5 ± 2 days after primary PCI. The secondary
2 endpoints included microvascular obstruction and intramyocardial hemorrhage
3 expressed as a percentage of LV mass by CMR, enzymatic infarct size by measuring
4 the area under the curve (AUC) of creatine kinase-myocardial band (CK-MB) within
5 72 hours after PCI, the AUC of cardiac troponin I (cTnI/cTnT), peak value of CK-MB
6 and peak value of cTnI/cTnT, ST segment resolution (%) immediately and 24h after
7 PCI according to electrocardiograph, TIMI flow grade, corrected TIMI frame count
8 (CTFC), TIMI myocardial perfusion grade (TMPG), myocardial salvage index,
9 myocardial edema, LV end-diastolic volume, LV end-systolic volume, LV ejection
10 fraction assessed by CMR. The incidence of MACCE (cardiovascular death, non-
11 fatal myocardial infarction, non-fatal stroke, emergency revascularization and re-
12 hospitalization for heart failure) and individual endpoint events at discharge and 30-
13 day follow-up were also secondary endpoints.

14 **Statistical analysis**

15 Sample size and power calculations based on our pilot data have been described
16 previously^{20, 21}. In brief, a mean infarct size in the placebo group and treatment group
17 were 28.0% and 24.0%, respectively (responding median values are 29.1% and
18 24.1%, respectively), and standard deviation (SD) was 11.33²⁰. We calculated that a
19 sample size of 260 patients would provide the trial with a statistical power of at least
20 80% to detect an expected difference at a single-sided alpha level of 2.5%. Allowing
21 for a drop-out rate of 20% not undergoing CMR resulted in a final sample size of 326
22 patients.

1 All efficacy analyses were performed according to the intention-to-treat principle.
2 For continuous variables, data were expressed as mean \pm SD or medians with
3 interquartile ranges (IQR) and compared between the 2 groups using an
4 independent-samples Student t test or the Wilcoxon rank sum test as appropriate.
5 For categorical variables, frequencies and percentages were compared by using the
6 Fisher exact test. Analysis of the primary endpoint and other CMR parameters was
7 performed by using a covariance analysis model with and without adjustment for the
8 randomization factors (center, age and TIMI flow grade pre-PCI), providing an
9 estimated treatment effect with a 95% confidence interval of infarct size between
10 groups. Secondary endpoints were analyzed using χ^2 test or Fisher exact test for
11 categorical data and student t test or Wilcoxon rank sum test for continuous
12 variables, as appropriate. The following pre-specified subgroup analyses to evaluate
13 the effect of Shenfu injection on primary endpoints were performed: age (< 65 years
14 versus \geq 65 years), sex, hypertension, diabetes, smoking, left ventricular ejection
15 fraction (\leq 50% versus > 50%), time from symptom onset to reperfusion time (\leq 6
16 hours versus > 6 hours), Killip class (Killip class I versus Killip class > I), pre-PCI
17 TIMI flow (TIMI 0 flow versus TIMI flow \geq 1), the type of P2Y₁₂ inhibitors (ticagrelor
18 versus clopidogrel), the type of anticoagulation agents (bivalirudin versus heparin)
19 and use of glycoprotein IIb/IIIa antagonists. All statistical analyses were performed
20 by SAS 9.4 (SAS Institute Inc., Cary, North Carolina). All statistical tests were two-
21 sided, and $P < 0.05$ was considered statistically significant.

22 **CMR Protocol and Analysis**

1 All patients undergone ECG-gated CMR imaging with 3.0-Tesla system (Magnetom
2 Verio, Siemens AG Healthcare, Erlangen, Germany) at 5 ± 2 days after PCI. And all
3 CMR studies were performed blinded to treatment allocation and according to a
4 centralized protocol. The detailed CMR protocol and analysis have been published²¹.
5 LV function was assessed by steady-state free precession sequence cine imaging in
6 short-axis view covering the whole LV without gap, with the parameters of repetition
7 time (TR)=3.5, echo time (TE)=1.5 ms, 25 phases, voxel size= $2.0 \times 1.6 \times 8$ mm³. LV
8 volumes, LVEF, and mass was calculated by using short-axis slices of cine images
9 covering the whole left ventricle. Assessment of AAR was defined by a T2-weighted
10 short-tau inversion-recovery spin echo sequence at apical, mid-ventricle, and basal
11 level on short-axis plane, with the parameters of TR/TE $2 \times$ R-R intervals/75 ms, voxel
12 size = $2.0 \times 1.6 \times 8$ mm³. AAR was considered as present if the signal intensity >2 SDs
13 above the mean signal in remote skeletal muscle and obtained by manually tracing
14 the hyperintense region on T2w-STIR. A hypointense area within the hyperintense
15 region was considered as IMH. Late gadolinium enhancement images were acquired
16 ten minutes after the intravenous administration of 0.2mmol/kg of contrast injection
17 (Magnevist, Bayer HealthCare Pharmaceuticals Inc., Germany) by using an
18 inversion recovery segmented 3D gradient echo sequence, with the parameters of
19 TR=3.5, TE=1.7 ms, temporal resolution=190 ms, voxel size $1.5 \times 1.7 \times 10$ mm³
20 interpolated into $0.74 \times 0.74 \times 5$ mm³ at short-axis and 2-, 4-chamber views.
21 Myocardial infarction was determined as hyper-enhanced myocardium [a signal
22 intensity >5 standard deviations (SDs) of remote normal myocardium]. MVO was

1 determined as hypo-enhanced core within the infarcted zone. Myocardial salvage
2 index is calculated as: $[(AAR - \text{infarct size})/AAR] \times 100\%$. The extent of the infarction,
3 MVO, IMH and AAR was expressed as a percentage of LV myocardial mass (%LV).
4 All CMR imaging was analyzed offline by blinded expert observers using CVI42
5 Version 5.13 (Cardiovascular Imaging, Calgary, Alberta, Canada).

6 **Results**

7 **Patients Characteristics**

8 The study flowchart is shown in Figure 1. A total of 351 patients planned to
9 undergoing primary PCI for acute anterior STEMI were screened and 295 patients
10 were randomized (144 to the Shenfu injection group; 151 to the placebo group). The
11 patients with a missing primary endpoint (infarct size measured by CMR) comprised
12 10 patients in the Shenfu injection and 12 patients in the placebo group. Thus, 273
13 patients (134 patients in the Shenfu injection group and 139 patients in the placebo
14 group) underwent CMR imaging and had the available data for the primary analysis.

15 The baseline characteristics of patients are shown in Table 1. The median age of
16 the study population was 56.5 (IQR: 48.0-65.0) years, and 83.4% were male. Except
17 for age, there were no major significances at baseline between the two groups.

18 Among included patients, 54.9% had hypertension, 24.4% had diabetes, and 15.3%
19 presented with known coronary artery disease. The two groups had a similar
20 hemodynamic status, in terms of blood pressure, heart rate and Killip class. Baseline
21 risk score, pharmacological treatment prior to PCI, different time intervals concerning

1 treatment, and blood results on admission were also well balanced between groups.

2 Procedural and angiographic data are shown in Table 2. Distribution of infarct-
3 related artery (LAD) stenosis location and number of diseased arteries were similar
4 between groups. There was a trend towards a higher incidence of pre-PCI TIMI 0 in
5 the Shenfu injection group compared with that in the placebo group. Stent
6 implantation was performed in 91.9% of patients, and drug-eluting stent was used in
7 all patients with stent implantation. Interventional and pharmacological treatment at
8 discharge were comparable between the two groups.

9 The baseline characteristics, procedural and angiographic data of patients who
10 completed CMR for primary analysis are shown in Table S2 and Table S3.

11 **CMR assessment**

12 Of 295 patients, 276 (93.6%) underwent CMR at a median of 5 days (IQR: 4-5). For
13 the primary endpoint (CMR-defined infarct size), 134 of 144 patients in the Shenfu
14 injection group and 139 of 151 patients in the placebo group had an accurate
15 endpoint assessment, respectively.

16 **Primary endpoint**

17 The primary endpoint of infarct size expressed as a percentage of LV mass is shown
18 in Table 3, Figure 2, Central Illustration and Supplemental Table 4. The unadjusted
19 infarct size revealed by CMR was not significantly reduced in the Shenfu injection
20 group compared with the placebo group (37.4% versus 37.5%; mean difference, -
21 0.04%; 95% CI: -3.45% to 3.37%; $P = 0.982$). On covariance analysis model with

1 adjustment for the randomization factors, the adjusted infarct size between groups
2 remained no significant difference (30.9% versus 31.2%; mean difference, -0.26%;
3 95%CI: -3.61% to 3.08%; $P = 0.877$).

4 There were no significant differences across the pre-specified subgroups for the
5 primary endpoint (Figure 3). Notably, in the subgroup of patients with age ≥ 65 years,
6 infarct size was numerically but not significantly decreased in the Shenfu injection
7 group (36.2% versus 40.2%, or a 3.99 reduction [95%CI: -10.27% to 2.29%], $P =$
8 0.209).

9 **Secondary endpoints**

10 There were no significant differences in the pre-specified secondary endpoints
11 defined by CMR, in terms of microvascular obstruction, intramyocardial hemorrhage,
12 myocardial salvage index, myocardial edema, LV end-diastolic volume, LV end-
13 systolic volume, and LV ejection fraction between the Shenfu injection and placebo
14 groups with and without adjustment, as shown in Table 3 and Table S4.

15 There were no significant differences by study treatment in the incidence of the
16 coronary-related secondary endpoints, including TIMI flow 3 post-PCI (94.8% versus
17 97.1%, $P = 0.324$), TMPG 3 post-PCI (91.7% versus 92.1%, $P = 0.914$), no-reflow
18 (0.0% versus 0.7%, $P = 1.000$), and slow-flow (3.0% versus 4.3%, $P = 0.750$).

19 Corrected TIMI frame count post-PCI, as a continue assessment for epicardial
20 reperfusion, showed no significant differences between the two treatment arms.

21 Infarct size by the AUC of CK-MB or cTnT over the initial 72 h post-PCI did not differ
22 between groups (Figure 4), as well as the peak value of CKMB and cTnT. Complete

1 ST-segment resolution immediately or at 24h post-PCI was also similar between
2 groups. High-sensitive C-reactive protein levels and BNP or NT-proBNP were not
3 significantly lower in the Shenfu injection group than in the placebo group at 24
4 hours, 72 hours and 5 days. Health-related quality of life scores (MIDAS score) was
5 not significantly different between groups at 6h or 30 days.

6 **Per-protocol analysis**

7 Following per-protocol analysis, there remained no reduction in infarct size in Shenfu
8 injection group compared with placebo group in unadjusted or adjusted analyses, as
9 well as other CMR parameters, as shown in Table S5, Table S6 and Figure S1.
10 Similarly, there were no significant differences between groups in terms of infarct
11 size by the AUC of CK-MB or cTnT over the initial 72h post-PCI (Figure S2).

12 **Clinical outcomes at discharge and at 30-day, severe adverse events, and** 13 **adverse events**

14 The clinical outcomes are described in Table 4. No significant difference was found
15 for the rate of MACCE at 30 days. At discharge, MACCE occurred in 2 patient (1.3%)
16 in the placebo group, and no MACCE occurred in the Shenfu injection group.
17 By 30 days, 1 patient (0.7%) in the Shenfu injection group and 3 patient (2.0%) in the
18 placebo group had died. Three deaths were secondary to cardiovascular causes (1
19 probable subacute stent thrombosis in the Shenfu injection group, and 1 ventricular
20 fibrillation and 1 cardiac rupture in the placebo group), another death was
21 attributable to infectious pneumonia in the placebo group. The rate of MACCE at 30
22 days was not significantly different between the two groups: 2 patient (1.4%) in the

1 Shenfu injection group and 4 patients (2.6%) in the placebo group, respectively ($P =$
2 0.685).

3 There were 9 patients (6.25%) with severe adverse events in the Shenfu injection
4 group and 11 patients (7.28%) in the placebo group at 30-day follow-up, with no
5 significant difference ($P = 0.819$, Table 5). Adverse events classified according to
6 System Organ Class are shown in Table S7. Rates of adverse events were similar
7 between the two groups (61.1% versus 63.6%, $P = 0.719$).

8 **DISCUSSION**

9 In this double-blind, placebo-controlled randomized clinical trial, intravenous Shenfu
10 injection administered prior to reperfusion and followed by once a day until 5 days
11 after primary PCI for STEMI did not reduce myocardial infarct size compared with
12 placebo. There was also no effect on any of the secondary endpoints. The drug was
13 safe and well tolerated.

14 Multiple mechanical and pharmacological strategies aimed at reducing infarct
15 size after STEMI have failed^{11, 22-27}. One major reason might be that key
16 mechanisms involved in the pathophysiology of reperfusion injury are manifold and
17 complex, all of which have been identified as therapeutic targets for inhibiting
18 myocardial injury²³. A single-target agent or intervention may be ineffective to
19 cardioprotection against reperfusion injury. In this regard, emerging studies
20 suggested that the adoption of multitargeted therapy directed to distinct targets may
21 provide synergistic cardioprotective effects, and further achieve the optimal

1 cardioprotection²⁸⁻³¹.

2 As a Chinese herbal formula, Shenfu injection has shown satisfactory
3 therapeutic efficacy in several other clinical setting including cardiogenic shock³²,
4 cardiac arrest¹⁷ and heart failure³³⁻³⁵, via the combination of multi-ingredients and
5 multitargets. Extensive evidence from animal studies has indicated that Shenfu
6 injection could effectively protect against sepsis-induced myocardial injury by
7 inhibiting mitochondrial apoptosis³⁶ and attenuating lipopolysaccharide-induced
8 myocardial inflammation³⁷, and it might regulate the expression of adenosine
9 receptors to ameliorate the ischemia-reperfusion injury³⁸. Moreover, our pilot study
10 showed that the use of Shenfu in STEMI patients was safe and there was a trend
11 towards reduction in CMR infarct size in the Shenfu injection group²⁰. However, the
12 RESTORE trial showed that there was no reduction of infarct size and other CMR
13 parameters in patients receiving Shenfu injection. These findings further reconfirmed
14 that reperfusion injury per se is a complex and multifactorial pathophysiological
15 process, with multiple mechanisms.

16 Based on prior studies and position papers^{2, 39, 40}, the RESTORE trial enrolled
17 high-risk STEMI patients, presenting with proximal or mid LAD occlusion (and
18 without prior myocardial infarction) prior to primary PCI (74.7% patients with pre-PCI
19 TIMI flow 0 or 1 in the primary analysis population). The study population thus
20 represents a highly selected cohort of patients with large infarcts, most likely to
21 benefit from a novel cardioprotective therapy. Several possible factors may explain
22 the lack of benefit of Shenfu injection in our study. First, one potential explanation

1 may be an imbalance in age and pre-PCI TIMI flow at baseline between groups.
2 Previous studies showed that age and pre-PCI TIMI flow grade 0 were the
3 determinates of infarct size^{41, 42}. Shenfu injection group had significantly higher rates
4 of pre-PCI TIMI flow grade 0 in the primary analysis population (80.6% versus
5 69.1%; P = 0.036, Supplemental Table 3) compared with the placebo group. This
6 discrepancy may contribute to the absence of the efficacy of Shenfu injection in
7 reducing the infarct size. Second, potential benefit of Shenfu injection cannot be
8 excluded in a certain subgroup of patients with severe hemodynamic changes
9 (cardiogenic shock or those in Killip class III-IV), who have greater opportunity to
10 obtain additional myocardial salvage, as well as those that are ineligible for CMR
11 imaging. Third, no dose-response studies for assessment of the optimal dose and
12 duration of Shenfu injection for myocardial infarction have been done, although the
13 dosage and duration in this study were based on prior clinical data and were limited
14 by the known side effects²⁰. The optimal required concentration of Shenfu injection
15 may be higher than were actually achieved in this study. And it is unclear whether or
16 not the dose and concentration of Shenfu injection achieved is optimal at the time of
17 reperfusion due to pharmacodynamic limitations. Future efforts should consider
18 blood sample storage at different time points to provide deeper insights in optimal
19 therapeutic concentrations. Finally, the failed translation from animal models to
20 clinical efficacy in ameliorating myocardial injury might result from the absence of
21 comorbidities and comedications in animal experiments.

22 Shenfu injection is a widely used drug with acceptable safety profiles.

1 Metabolism and nutrition disorders (e.g. hypokalemia), hepatobiliary system
2 disorders (e.g. liver injury) and gastrointestinal disorders (e.g. nausea) represent
3 well-known, mostly mild side effects of Shenfu injection and were not more
4 frequently reported in the Shenfu injection group.

5 **Limitations**

6 This study has limitations. First, the present trial included anterior STEMI
7 patients with proximal/mid LAD occlusion. Subjects with severe heart failure (Killip
8 class III or above) were excluded. Thus, the study results might not be applicable to
9 other sites of myocardial infarction or critically ill patients. Secondly, only a single
10 dose and duration of Shenfu injection was evaluated in this trial. It is possible that
11 the Shenfu dose regimen and duration were insufficient to achieve the optimal
12 cardioprotective effect for STEMI patients. Third, the emergency of the national
13 COVID-19 pandemic during the study period raised a big obstacle including pauses
14 in enrolment due to lockdown, and limited completion of CMR imaging due to
15 potential COVID-19 infection.

16 **Conclusions**

17 Among patients with acute anterior STEMI presenting within 12 hours of symptoms,
18 adjunctive Shenfu injection before reperfusion was safe but did not mitigate
19 myocardial injury in the contemporary era.

20 **Acknowledgements**

21 NA.

1 **Sources of Funding**

2 This study is financed by research grant from China Resources Sanjiu Medical &
3 Pharmaceutical Co., Ltd. and partially funded by National Key R&D Program of
4 China (2022YFC2505600), Beijing Municipal Natural Science Foundation Grant
5 (JQ24039), Beijing Hospitals Authority Clinical Medicine Development of Special
6 Funding Support (ZLRK202318), and Beijing Municipal Science & Technology
7 Commission, China (Z221100003522027).

8 **Disclosures**

9 Dr. Shaoping Nie: research grants to the institution from Boston Scientific, Abbott,
10 Jiangsu Hengrui Pharmaceuticals, China Resources Sanjiu Medical &
11 Pharmaceuticals, East China Pharmaceuticals. The rest of the authors have no
12 relevant relationships to disclose.

1 REFERENCES

- 2 1. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ,
3 Dan GA, Dweck MR, Galbraith M, et al. 2023 ESC Guidelines for the management of
4 acute coronary syndromes. *Eur Heart J* 2023;44(38):3720-3826.
5 <https://doi.org/10.1093/eurheartj/ehad191>
- 6 2. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Kloner
7 RA, Ovize M, Yellon DM, Garcia-Dorado D. Targeting reperfusion injury in patients
8 with ST-segment elevation myocardial infarction: trials and tribulations. *Eur Heart J*
9 2017;38(13):935-941. <https://doi.org/10.1093/eurheartj/ehw145>
- 10 3. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected
11 therapeutic target. *J Clin Invest* 2013;123(1):92-100.
12 <https://doi.org/10.1172/JCI62874>
- 13 4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med*
14 2007;357(11):1121-1135. <https://doi.org/10.1056/NEJMra071667>
- 15 5. Qiao S, Zhang W, Yin Y, Wei Z, Chen F, Zhao J, Sun X, Mu D, Xie J, Xu B.
16 Extracellular vesicles derived from Kruppel-Like Factor 2-overexpressing endothelial
17 cells attenuate myocardial ischemia-reperfusion injury by preventing Ly6C(high)
18 monocyte recruitment. *Theranostics* 2020;10(25):11562-11579.
19 <https://doi.org/10.7150/thno.45459>
- 20 6. Mendieta G, Ben-Aicha S, Gutierrez M, Casani L, Arzanauskaite M, Carreras F,
21 Sabate M, Badimon L, Vilahur G. Intravenous Statin Administration During
22 Myocardial Infarction Compared With Oral Post-Infarct Administration. *J Am Coll*

- 1 *Cardiol* 2020;75(12):1386-1402. <https://doi.org/10.1016/j.jacc.2020.01.042>
- 2 7. He W, McCarroll CS, Nather K, Ford K, Mangion K, Riddell A, O'Toole D, Zaeri A,
3 Corcoran D, Carrick D, et al. Inhibition of myocardial cathepsin-L release during
4 reperfusion following myocardial infarction improves cardiac function and reduces
5 infarct size. *Cardiovasc Res* 2022;118(6):1535-1547.
6 <https://doi.org/10.1093/cvr/cvab204>
- 7 8. Sayour AA, Celeng C, Olah A, Ruppert M, Merkely B, Radovits T. Sodium-
8 glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal
9 models of myocardial ischaemia-reperfusion injury: a meta-analysis. *Diabetologia*
10 2021;64(4):737-748. <https://doi.org/10.1007/s00125-020-05359-2>
- 11 9. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in
12 perspective. *Nat Rev Cardiol* 2020;17(12):773-789. [https://doi.org/10.1038/s41569-](https://doi.org/10.1038/s41569-020-0403-y)
13 [020-0403-y](https://doi.org/10.1038/s41569-020-0403-y)
- 14 10. Davidson SM, Ferdinandy P, Andreadou I, Botker HE, Heusch G, Ibanez B,
15 Ovize M, Schulz R, Yellon DM, Hausenloy DJ, et al. Multitarget Strategies to Reduce
16 Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. *J Am Coll*
17 *Cardiol* 2019;73(1):89-99. <https://doi.org/10.1016/j.jacc.2018.09.086>
- 18 11. Stahli BE, Klingenberg R, Heg D, Branca M, Manka R, Kapos I, Muggler O,
19 Denegri A, Kesterke R, Berger F, et al. Mammalian Target of Rapamycin Inhibition in
20 Patients With ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol*
21 2022;80(19):1802-1814. <https://doi.org/10.1016/j.jacc.2022.08.747>
- 22 12. Fordyce CB, Gersh BJ, Stone GW, Granger CB. Novel therapeutics in

- 1 myocardial infarction: targeting microvascular dysfunction and reperfusion injury.
2 *Trends Pharmacol Sci* 2015;36(9):605-616. <https://doi.org/10.1016/j.tips.2015.06.004>
- 3 13. Wang X, Guo Q, Guo R, Guo Y, Yan Y, Gong W, Zheng W, Wang H, Ai H, Que B,
4 et al. Coronary angiography-derived index of microcirculatory resistance and
5 evolution of infarct pathology after ST-segment-elevation myocardial infarction. *Eur*
6 *Heart J Cardiovasc Imaging* 2023;24(12):1640-1652.
7 <https://doi.org/10.1093/ehjci/jead141>
- 8 14. Guo Y, Guo Q, Guo R, Yan Y, Gong W, Zheng W, Wang H, Xu L, Wang X, Nie S.
9 Glycemic Status and Myocardial Strain by Cardiac MRI in Patients With ST-Segment
10 Elevation Myocardial Infarction. *J Magn Reson Imaging* 2024;59(2):548-560.
11 <https://doi.org/10.1002/jmri.28794>
- 12 15. Song Y, Zhang N, Shi S, Li J, Zhang Q, Zhao Y, Jiang Y, Tu P. Large-scale
13 qualitative and quantitative characterization of components in Shenfu injection by
14 integrating hydrophilic interaction chromatography, reversed phase liquid
15 chromatography, and tandem mass spectrometry. *J Chromatogr A* 2015;1407:106-
16 118. <https://doi.org/10.1016/j.chroma.2015.06.041>
- 17 16. Yang H, Liu L, Gao W, Liu K, Qi LW, Li P. Direct and comprehensive analysis of
18 ginsenosides and diterpene alkaloids in Shenfu injection by combinatory liquid
19 chromatography-mass spectrometric techniques. *J Pharm Biomed Anal* 2014;92:13-
20 21. <https://doi.org/10.1016/j.jpba.2013.12.041>
- 21 17. Zhang Q, Li C, Shao F, Zhao L, Wang M, Fang Y. Efficacy and Safety of
22 Combination Therapy of Shenfu Injection and Postresuscitation Bundle in Patients

- 1 With Return of Spontaneous Circulation After In-Hospital Cardiac Arrest: A
2 Randomized, Assessor-Blinded, Controlled Trial. *Crit Care Med* 2017;45(10):1587-
3 1595. <https://doi.org/10.1097/CCM.0000000000002570>
- 4 18. Li X, Huang F, Zhu L, Luo T, Zhang Y, Gu H, Guo L, Mao S. Effects of
5 combination therapy with Shenfu Injection in critically ill patients with septic shock
6 receiving mechanical ventilation: A multicentric, real-world study. *Front Pharmacol*
7 2022;13:1041326. <https://doi.org/10.3389/fphar.2022.1041326>
- 8 19. Wen ZG, Zhang QQ, Zhang LL, Shen MF, Huang YS, Zhao LH. Efficacy and
9 safety of traditional chinese medicine treatment for overweight and obese
10 individuals: A systematic review and meta-analysis. *Front Pharmacol*
11 2022;13:964495. <https://doi.org/10.3389/fphar.2022.964495>
- 12 20. Wang X, Miao H, Yan Y, Guo R, Gong W, He Y, Wang H, Ma X, Nie S. Effect of
13 Shenfu Injection on Reperfusion Injury in Patients Undergoing Primary Percutaneous
14 Coronary Intervention for ST Segment Elevation Myocardial Infarction: A Pilot
15 Randomized Clinical Trial. *Front Cardiovasc Med* 2021;8:736526.
16 <https://doi.org/10.3389/fcvm.2021.736526>
- 17 21. Wang X, Guo R, Guo Y, Guo Q, Yan Y, Gong W, Zheng W, Wang H, Xu L, Ai H,
18 et al. Rationale and design of the RESTORE trial: A multicenter, randomized, double-
19 blinded, parallel-group, placebo-controlled trial to evaluate the effect of Shenfu
20 injection on myocardial injury in STEMI patients after primary PCI. *Am Heart J*
21 2023;260:9-17. <https://doi.org/10.1016/j.ahj.2023.02.005>
- 22 22. Patel MR, Smalling RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Chew D,

- 1 Cohen M, French J, Perera D, et al. Intra-aortic balloon counterpulsation and infarct
2 size in patients with acute anterior myocardial infarction without shock: the CRISP
3 AMI randomized trial. *JAMA* 2011;306(12):1329-1337.
4 <https://doi.org/10.1001/jama.2011.1280>
- 5 23. Gibson CM, Giugliano RP, Kloner RA, Bode C, Tendera M, Janosi A, Merkely B,
6 Godlewski J, Halaby R, Korjian S, et al. EMBRACE STEMI study: a Phase 2a trial to
7 evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion
8 injury in patients undergoing primary percutaneous coronary intervention. *Eur Heart*
9 *J* 2016;37(16):1296-1303. <https://doi.org/10.1093/eurheartj/ehv597>
- 10 24. Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T, Ivanes F,
11 Dubreuil O, Biere L, Hayek A, et al. Effect of Colchicine on Myocardial Injury in Acute
12 Myocardial Infarction. *Circulation* 2021;144(11):859-869.
13 <https://doi.org/10.1161/CIRCULATIONAHA.121.056177>
- 14 25. Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato
15 Y, Lu MT, Kuder J, Murphy SA, et al. Randomized, Placebo-Controlled Phase 2b
16 Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin
17 Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction:
18 Results of REAL-TIMI 63B. *Circulation* 2022;146(12):907-916.
19 <https://doi.org/10.1161/CIRCULATIONAHA.122.059325>
- 20 26. de Koning MLY, van Dorp P, Assa S, Pundziute-Do Prado G, Voskuil M, Antonio
21 RL, Veen D, Leiner T, Sibeijn-Kuiper AJ, van Goor H, et al. Sodium Thiosulfate in
22 Acute Myocardial Infarction: A Randomized Clinical Trial. *JACC Basic Transl Sci*

- 1 2023;8(10):1285-1294. <https://doi.org/10.1016/j.jacbts.2023.06.001>
- 2 27. Noaman S, Neil C, O'Brien J, Frenneaux M, Hare J, Wang B, Yee Tai T, Theuerle
3 J, Shaw J, Stub D, et al. UpStreAm doxycycline in ST-eLeVation myocArdial
4 infarction: targetinG infarct hEaling and Modulatlon (SALVAGE-MI trial). *Eur Heart J*
5 *Acute Cardiovasc Care* 2023;12(3):143-152. <https://doi.org/10.1093/ehjacc/zuac161>
- 6 28. Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A,
7 Erbs S, Lurz P, Boudriot E, et al. Cardioprotection by combined intrahospital remote
8 ischaemic preconditioning and postconditioning in ST-elevation myocardial
9 infarction: the randomized LIPSIA CONDITIONING trial. *Eur Heart J*
10 2015;36(44):3049-3057. <https://doi.org/10.1093/eurheartj/ehv463>
- 11 29. Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L,
12 Mateos A, Fernandez-Ortiz A, Garcia-Ruiz JM, Garcia-Alvarez A, Iniguez A, et al.
13 Effect of early metoprolol on infarct size in ST-segment-elevation myocardial
14 infarction patients undergoing primary percutaneous coronary intervention: the Effect
15 of Metoprolol in Cardioprotection During an Acute Myocardial Infarction
16 (METOCARD-CNIC) trial. *Circulation* 2013;128(14):1495-1503.
17 <https://doi.org/10.1161/CIRCULATIONAHA.113.003653>
- 18 30. Roolvink V, Ibanez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A,
19 Dambrink JE, Escalera N, Lipsic E, Albarran A, et al. Early Intravenous Beta-
20 Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before
21 Primary Percutaneous Coronary Intervention. *J Am Coll Cardiol* 2016;67(23):2705-
22 2715. <https://doi.org/10.1016/j.jacc.2016.03.522>

- 1 31. Pasupathy S, Tavella R, Grover S, Raman B, Procter NEK, Du YT, Mahadavan
2 G, Stafford I, Heresztyn T, Holmes A, et al. Early Use of N-acetylcysteine With Nitrate
3 Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-
4 Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the
5 NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). *Circulation*
6 2017;136(10):894-903. <https://doi.org/10.1161/CIRCULATIONAHA.117.027575>
- 7 32. Shao F, Li H, Li D, Li C. Effects of Shenfu injection on survival and neurological
8 outcome after out-of-hospital cardiac arrest: A randomised controlled trial.
9 *Resuscitation* 2020;150:139-144. <https://doi.org/10.1016/j.resuscitation.2019.11.010>
- 10 33. Wu Y, Li S, Li Z, Mo Z, Luo Z, Li D, Wang D, Zhu W, Ding B. Efficacy and safety
11 of Shenfu injection for the treatment of post-acute myocardial infarction heart failure:
12 A systematic review and meta-analysis. *Front Pharmacol* 2022;13:1027131.
13 <https://doi.org/10.3389/fphar.2022.1027131>
- 14 34. Tao L, Mo Z, Li Z, Li S, Luo Z, Li D, Wang D, Zhu W, Ding B. Efficacy and Safety
15 of Shenfu Injection on Acute Heart Failure: A Systematic Review and Meta-Analysis.
16 *Phytomedicine* 2023;110:154641. <https://doi.org/10.1016/j.phymed.2023.154641>
- 17 35. Wang X, Zhao Z, Mao J, Du T, Chen Y, Xu H, Liu N, Wang X, Wu J, Li R, et al.
18 Randomized, Double-Blinded, Multicenter, Placebo-Controlled Trial of Shenfu
19 Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase
20 of Symptom Aggravation (Yang and Qi Deficiency Syndrome). *Evid Based*
21 *Complement Alternat Med* 2019;2019:9297163.
22 <https://doi.org/10.1155/2019/9297163>

- 1 36. Xu P, Zhang WQ, Xie J, Wen YS, Zhang GX, Lu SQ. Shenfu injection prevents
2 sepsis-induced myocardial injury by inhibiting mitochondrial apoptosis. *J*
3 *Ethnopharmacol* 2020;261:113068. <https://doi.org/10.1016/j.jep.2020.113068>
- 4 37. Chen RJ, Rui QL, Wang Q, Tian F, Wu J, Kong XQ. Shenfu injection attenuates
5 lipopolysaccharide-induced myocardial inflammation and apoptosis in rats. *Chin J*
6 *Nat Med* 2020;18(3):226-233. [https://doi.org/10.1016/S1875-5364\(20\)30025-X](https://doi.org/10.1016/S1875-5364(20)30025-X)
- 7 38. Wang J, Wang X, Wan W, Guo Y, Cui Y, Liu W, Guo F. Effects of Shenfu injection
8 on myocardial adenosine receptors in rats with myocardial ischemia-reperfusion
9 postconditioning. *Hum Exp Toxicol* 2021;40(12_suppl):S300-S309.
10 <https://doi.org/10.1177/096032712111041668>
- 11 39. Hausenloy DJ, Garcia-Dorado D, Botker HE, Davidson SM, Downey J, Engel FB,
12 Jennings R, Lecour S, Leor J, Madonna R, et al. Novel targets and future strategies
13 for acute cardioprotection: Position Paper of the European Society of Cardiology
14 Working Group on Cellular Biology of the Heart. *Cardiovasc Res* 2017;113(6):564-
15 585. <https://doi.org/10.1093/cvr/cvx049>
- 16 40. Bulluck H, Hammond-Haley M, Weinmann S, Martinez-Macias R, Hausenloy DJ.
17 Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies: Insights From
18 Randomized Controlled Trials. *JACC Cardiovasc Imaging* 2017;10(3):230-240.
19 <https://doi.org/10.1016/j.jcmg.2017.01.008>
- 20 41. Park IH, Cho HK, Oh JH, Chun WJ, Park YH, Song YB, Hahn JY, Choi SH, Lee
21 SC, Gwon HC, et al. Old Age and Myocardial Injury in ST-Segment Elevation
22 Myocardial Infarction. *Am J Med Sci* 2021;362(6):592-600.

1 <https://doi.org/10.1016/j.amjms.2021.06.023>

2 42. Patel MR, Worthley SG, Stebbins A, Dill T, Rademakers FE, Valeti US, Barsness
3 GW, Van de Werf F, Hamm CW, Armstrong PW, et al. Pexelizumab and infarct size in
4 patients with acute myocardial infarction undergoing primary percutaneous coronary
5 Intervention: a delayed enhancement cardiac magnetic resonance substudy from the
6 APEX-AMI trial. *JACC Cardiovasc Imaging* 2010;3(1):52-60.

7 <https://doi.org/10.1016/j.jcmg.2009.09.014>

8

9

Table 1. Baseline Clinical Characteristics

Baseline Characteristics	Total (N = 295)	Shenfu injection group (N = 144)	Placebo group (N = 151)	P value
Demographics				
Age, years	56.5 (48.0, 65.0)	55.5 (45.0, 64.0)	59.0 (51.0, 66.0)	0.017
Male, n (%)	246 (83.4)	121 (84.0)	125 (82.8)	0.774
BMI, kg/m ²	25.1 ± 3.1	25.3 ± 3.0	24.8 ± 3.1	0.135
Medical history				
Hypertension, n (%)	162 (54.9)	83 (57.6)	79 (52.3)	0.359
Diabetes, n (%)	72 (24.4)	34 (23.6)	38 (25.2)	0.756
Prior stroke, n (%)	12 (4.1)	8 (5.6)	4 (2.6)	0.207
Dyslipidemia, n (%)	105 (35.6)	50 (34.7)	55 (36.4)	0.760
Smoking, n (%)				0.669
Current	138 (46.8)	67 (46.5)	71 (47.0)	
Former	15 (5.1)	9 (6.3)	6 (4.0)	

Never	142 (48.1)	68 (47.2)	74 (49.0)	
Coronary artery disease, n (%)	45 (15.3)	24 (16.7)	21 (13.9)	0.510
Heart failure, n (%)	2 (0.7)	1 (0.7)	1 (0.7)	1.000
Chronic renal failure, n (%)	2 (0.7)	1 (0.7)	1 (0.7)	1.000
Peripheral artery disease, n (%)	8 (2.7)	4 (2.8)	4 (2.7)	1.000
Clinical presentation				
SBP, mmHg	130.0 (118.0, 142.0)	130.0 (118.0, 141.0)	130.0 (118.0, 143.0)	0.694
DBP, mmHg	82.5 (75.0, 92.0)	83.0 (72.0, 93.0)	81.0 (75.0, 92.0)	0.932
Heart rate, beats/min	81.0 (71.0, 90.0)	80.0 (70.0,91.0)	91.0 (72.0,90.0)	0.759
Killip class I at recruitment, n (%)	227 (77.0)	114 (79.2)	113 (74.8)	0.704
Time to treatment, hour				
From symptom onset to first medical contact	2.0 (0.8, 3.7)	2.0 (1.0, 3.7)	2.0 (0.8, 3.8)	0.601
From symptom onset to	3.4 (2.0, 5.3)	3.3 (2.0, 6.0)	3.4 (2.0, 5.1)	0.538

arrival at primary PCI center				
From symptom onset to reperfusion time	4.0 (2.8, 6.1)	4.0 (2.8, 6.3)	4.0 (2.7, 5.8)	0.591
From arrival at primary PCI center to reperfusion time	0.6 (0.3, 0.9)	0.6 (0.2, 0.9)	0.6 (0.4, 0.9)	0.600
GRACE risk score	127.2 ± 30.9	124.4 ± 32.6	129.8 ± 29.1	0.137
CRUSADE risk score	20.0 (12.0, 28.0)	19.0 (13.0, 27.0)	20.0 (11.0, 28.0)	0.327
Treatment prior to primary PCI				
Aspirin losing dose, n (%)	286 (97.3)	139 (96.5)	147 (98.0)	0.745
P2Y ₁₂ inhibitor loading dose, n (%)	287 (97.6)	141 (97.9)	146 (97.3)	0.723
Statin, n (%)	97 (33.0)	50 (34.7)	47 (31.3)	0.511
Initial blood results on admission				
Hemoglobin, g/L	151.0 (141.0, 160.0)	151.0 (141.0, 160.0)	151.0 (140.0, 158.0)	0.414

White blood cell counting, 10 ¹² /L	10.5 (8.6, 13.4)	10.8 (8.7, 14.1)	10.2 (8.6, 12.5)	0.194
HbA1c, %	6.0 (5.6, 6.9)	6.0 (5.6, 6.9)	6.0 (5.6, 6.9)	0.708
Fasting blood glucose, mmol/L	8.0 (6.5, 10.1)	8.0 (6.5, 10.1)	7.9 (6.6, 9.8)	0.630
High-sensitive CRP, mg/dL	2.0 (1.3, 3.8)	2.1 (1.3, 3.4)	2.0 (1.2, 4.8)	0.850
Scr, µmol/L	66.8 (57.3, 79.9)	67.7 (60.0, 80.6)	65.4 (56.0, 78.0)	0.090

Data are presented as mean ± SD, median (IQR), or n (%). BMI, body-mass index; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin A1c; hs-CRP, high-sensitive C-reactive protein; SBP, systolic blood pressure; Scr, serum creatinine; PCI, percutaneous coronary intervention.

Table 2. Procedural Characteristics and Medication at Discharge

Characteristics	Total (N = 295)	Shenfu injection group (N = 144)	Placebo group (N = 151)	P value
Radial artery access, n (%)	289 (98.0)	139 (96.5)	150 (99.3)	0.113
Infarct-related artery (LAD) stenosis location, n (%)				
Proximal lesion	222 (75.3)	108 (75.0)	114 (75.5)	0.921
Middle lesion	118 (40.0)	59 (41.0)	59 (39.1)	0.739
Distal lesion	25 (8.5)	14 (9.7)	11 (7.3)	0.452
Number of diseased arteries, n (%)				0.482
1	113 (38.3)	58 (40.3)	55 (36.4)	
2	96 (32.5)	42 (29.2)	54 (35.8)	
3	86 (29.2)	44 (30.6)	42 (27.8)	
TIMI flow grade 0 pre-PCI, n (%)	223 (75.6)	115 (79.9)	108 (71.5)	0.105
TIMI flow pre-PCI, n (%)				0.294

0	223 (75.6)	115 (79.9)	108 (71.5)	
1	53 (18.0)	23 (15.98)	30 (19.9)	
2	11 (3.7)	4 (2.8)	7 (4.6)	
3	8 (2.7)	2 (1.4)	6 (4.0)	
TIMI myocardial perfusion grade pre-PCI, n/N (%)				0.445
0	267/294 (90.8)	134/143 (93.7)	133/151 (88.1)	
1	4/294 (1.4)	1/143 (0.7)	3/151 (2.0)	
2	6/294 (2.0)	2/143 (1.4)	4/151 (2.7)	
3	17/294 (5.8)	6/143 (4.2)	11/151 (7.3)	
Successful PCI, n (%)	295 (100.0)	144 (100.0)	151 (100.0)	-
Balloon angioplasty only, n (%)	24 (8.1)	10 (6.9)	14 (9.3)	0.465
Stent implantation, n (%)	271 (91.9)	134 (93.1)	137 (90.7)	0.465
Type of stent implantation, n (%)				-
Drug-eluting stent	271 (100.0)	134 (100.0)	137 (100.0)	

Bare-metal stent	0 (0.0)	0 (0.0)	0 (0.0)	
Location of stent implantation, n (%)				0.476
Proximal	176 (64.9)	84 (62.7)	92 (67.2)	
Middle	81 (29.9)	41 (30.6)	40 (29.2)	
Proximal-middle	14 (5.2)	9 (6.7)	5 (3.7)	
Total No. of stents deployed, n/N (%)				0.772
0	24/294 (8.2)	10/143 (7.0)	14/151 (9.3)	
1	208/294 (77.0)	103/143 (72.0)	105/151 (69.5)	
2	52/294 (19.3)	24/143 (16.8)	28/151 (18.5)	
≥ 3	10/294 (3.4)	6/143 (4.2)	4/151 (2.6)	
GPI use during intervention, n (%)	35 (11.9)	17 (11.8)	18 (11.9)	0.976
Thrombus aspiration, n/N (%)	120/294 (40.8)	64/144 (44.4)	56/150 (37.3)	0.215
Anticoagulation agents, n/N (%)				0.677
Bivalirudin	17/281 (6.0)	9/135 (6.7)	8/146 (5.5)	
Heparin	264/281 (94.0)	126/135 (93.3)	138/146 (94.5)	

IABP, n (%)	5 (1.7)	3 (2.1)	2 (1.3)	0.678
Medication at discharge				
Aspirin, n/N (%)	284/289 (98.3)	137/142 (96.5)	147/147 (100.0)	0.028
P2Y12 inhibitor, n/N (%)	288/289 (99.7)	142/142 (100.0)	146/147 (99.3)	1.000
Clopidogrel, n/N (%)	38/288 (13.2)	20/142 (14.1)	18/146 (12.3)	0.660
Ticagrelor, n/N (%)	249/288 (86.5)	123/142 (86.6)	126/146 (86.3)	0.937
β-Blockers, n/N (%)	246/288 (85.1)	119/142 (83.8)	127/146 (86.4)	0.536
ACEI or ARB, n/N (%)	144/289 (49.8)	76/141 (53.5)	68/146 (46.3)	0.217
MRA, n/N (%)	92/287 (32.1)	47/287 (33.3)	45/287 (30.8)	0.649
Statins, n/N (%)	281/289 (97.2)	139/142 (97.9)	142/147 (96.6)	0.723
Diuretics, n/N (%)	119/287 (41.5)	60/141 (42.6)	59/146 (40.4)	0.713

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; GPI, glycoprotein IIb/IIIa inhibitor; IABP, intra-aortic balloon pump; LAD, left anterior descending; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.

Table 3. Prespecified Primary and Secondary Endpoints

Outcomes	Shenfu injection group (N = 134)	Placebo group (N = 139)	Between-group difference (95% CI)	P value
Primary endpoint				
Infarct size at 5 ± 2 days, % LV mass	37.4 ± 14.1	37.5 ± 14.5	-0.04(-3.45,3.37)	0.982
Secondary endpoints				
MVO at 5 ± 2 days, % LV mass	1.7 (0.0, 4.6)	0.7 (0.0, 4.6)	0.39 (-0.60, 1.39)	0.118
IMH at 5 ± 2 days, % LV mass	0.1 (0.0, 1.4)	0.0 (0.0, 0.9)	0.18 (-0.21, 0.58)	0.153
MSI at 5 ± 2 days, %	36.7 ± 18.4	38.0 ± 17.7	-1.39 (-5.72, 2.95)	0.529
AAR at 5 ± 2 days, % LV mass	59.9 (50.6, 68.0)	60.2 (53.0, 67.1)	-0.75 (-4.15, 2.65)	0.654
LVEF at 5 ± 2 days, %	47.5 ± 9.8	47.9 ± 10.5	-0.40 (-2.82, 2.02)	0.747
LVEDV at 5 ± 2 days, mL	129.8 ± 29.7	131.7 ± 31.3	-1.84 (-9.13, 5.44)	0.619
LVESV at 5 ± 2 days, mL	68.8 ± 22.9	70.1 ± 27.0	-1.23 (-7.22, 4.75)	0.800
TIMI flow 3 post-PCI, n (%)	127 (94.8)	135 (97.1)	-	0.324
TIMI myocardial perfusion grade 3 post-PCI, n/N (%)	122/133 (91.7)	128/139 (92.1)	-	0.914
Corrected TIMI frame count post-PCI	11 (8, 15)	11.5 (8, 16)	-0.22(-1.93, 1.49)	0.913

Peak value of CK-MB, ng/mL	217.3 (86.4, 293.0)	193.2 (80.0, 290.7)	-	0.445
Peak value of cTnT, ng/mL	5.7 (3.7, 10.0)	8.73 (4.5, 10.0)	-	0.884
CK-MB, AUC	774.8 (361.0, 1155.0)	735.1 (334.2, 1021.8)	-	0.337
cTnT, AUC	35.0 (20.2, 67.1)	38.7 (16.0, 54.6)	-	0.917
Complete ST-segment resolution immediately post-PCI, n/N (%)	29/114 (25.4)	29/111 (26.1)	-	0.906
Complete ST-segment resolution 24h post-PCI	45/109 (41.3)	46/113 (40.7)	-	0.930
Slow flow during procedure, n (%)	4 (3.0)	6 (4.3)	-	0.750
No-flow during procedure, n (%)	0 (0.0)	1 (0.7)	-	1.000
Malignant arrhythmia during PCI, n (%)	0 (0.0)	0 (0.0)	-	-
Hs-CRP, mg/dL				
Hs-CRP 24 hours after PCI	10.9 (5.0, 20.4)	11.6 (5.6, 20.0)	-154.06 (-445.82, 137.71)	0.709
Hs-CRP 72 hours after PCI	14.4 (8.1, 32.8)	17.3 (7.7, 36.1)	-4.04 (-11.95, 3.87)	0.465
Hs-CRP 5 days after PCI	9.7 (5.4, 23.2)	11.0 (5.2, 24.6)	-2.15 (-7.84, 3.53)	0.944
BNP, pg/mL				

BNP 24 hours after PCI	363.0 (196.0, 740.0)	347.5 (179.8, 668.0)	55.87 (-249.42, 361.16)	0.738
BNP 72 hours after PCI	200.0 (98.0, 515.0)	194.0 (111.0, 623.0)	-64.47 (-466.67, 337.74)	0.775
BNP 5 days after PCI	211.0 (114.8, 441.0)	198.0 (109.8, 409.0)	-3.59 (-227.72, 220.55)	0.768
NT-proBNP, pg/mL				
NT-proBNP 24 hours after PCI	1420.0 (772.0, 2604.0)	1214.0 (848.0, 1849.0)	530.30 (-277.33, 1337.94)	0.572
NT-proBNP 72 hours after PCI	743.0 (267.0, 1378.0)	950.0 (594.0, 1324.0)	-285.50 (-1205.71, 634.72)	0.345
NT-proBNP 5 days after PCI	633.0 (226.0, 1120.0)	645.5 (419.0, 1079.0)	-82.30 (-710.60, 546.01)	0.521
MIDAS score 6h post-PCI	59 (46, 98)	61 (47, 98)	-0.74 (-7.81, 6.34)	0.780
MIDAS score 30d post-PCI	53 (40, 74)	54 (71, 78)	-0.69 (-5.77, 4.39)	0.928

AAR, area at risk; AUC, area under curve; BNP, brain natriuretic peptide; CK-MB, creatine kinase-myocardial band; cTnI, cardiac troponin I; cTnT, cardiac troponin T; hs-CRP, high-sensitive C-reactive protein; IMH, intra-myocardial hemorrhage; LV, left ventricular; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; MIDAS, myocardial infarction dimensional assessment scale; MVO, microvascular obstruction; MSI, myocardial salvage index; NT-proBNP, N-terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.

Table 4. Main Adverse Cardiovascular and Cerebrovascular at Discharge and 30 Days after PCI

Main adverse cardiovascular and cerebrovascular events	Shenfu injection group (N = 144)	Placebo group (N = 151)	P value
MACCE at discharge, n (%)	0 (0.0)	2 (1.3)	0.499
Cardiovascular death, n (%)	0 (0.0)	1 (0.7)	1.000
Non-fatal myocardial infarction, n (%)	0 (0.0)	0 (0.0)	-
Non-fatal stroke, n (%)	0 (0.0)	0 (0.0)	-
Emergency revascularization, n (%)	0 (0.0)	1 (0.7)	1.000
MACCE at 30 days after PCI, n (%)	2 (1.4)	4 (2.6)	0.685
Cardiovascular death, n (%)	1 (0.7)	2 (1.3)	1.000
Non-fatal myocardial infarction, n (%)	0 (0.0)	0 (0.0)	-
Non-fatal stroke, n (%)	1 (0.7)	0 (0.0)	0.488
Emergency revascularization, n (%)	0 (0.0)	1 (0.7)	1.000
Re-hospitalization for heart failure, n (%)	0 (0.0)	1 (0.7)	1.000

MACCE, main adverse cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention.


Table 5. Severe Adverse Events

Events	Shenfu injection group (N = 144)	Placebo group (N = 151)	<i>P</i> value
Severe adverse events (at least one), n (%)	9 (6.3)	11 (7.3)	0.819
All-cause death, n (%)	1 (0.7)	3 (2.0)	0.623
Cardiovascular death, n (%)	1 (0.7)	2(1.3)	1.000
Non-cardiovascular death, n (%)	0 (0.0)	1(0.7)	1.000
Congestive heart failure, n (%)	1 (0.7)	4(2.6)	0.371
Cardiac shock, n (%)	1 (0.7)	1(0.7)	1.000
Cardiac rupture, n (%)	0 (0.0)	1(0.7)	1.000
Ventricular fibrillation, n (%)	1 (0.7)	2(1.3)	1.000
Stent thrombosis, n (%)	0 (0.0)	1 (0.7)	1.000
Angina, n (%)	3 (2.1)	0 (0.0)	0.115
Infectious pneumonia, n (%)	0 (0.0)	1 (0.7)	1.000
Stroke, n (%)	1 (0.7)	0 (0.0)	0.488
Respiratory failure, n (%)	1 (0.7)	0 (0.0)	0.488
Allergic shock, n (%)	0 (0.0)	1 (0.7)	1.000

Nephrotic syndrome, n (%)	0 (0.0)	1 (0.7)	1.000
Hypotension, n (%)	0 (0.0)	1 (0.7)	1.000


Figures and Figure Legends

Figure 1: Flowchart of the RESTORE trial




CMR, cardiac magnetic resonance; LGE, late gadolinium enhanced; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

Figure 2: Primary endpoint analyses



CI, confidence interval; CMR, cardiac magnetic resonance.


Figure 3: Forest Plot for the Effect of Shenfu Injection on Infarct Size in Pre-specified Subgroups



Results are expressed as [n] mean (SD).

CI, confidence interval; LVEF, left ventricular ejection fraction; GPI, glycoprotein IIb/IIIa inhibitor; PCI, percutaneous coronary intervention; SD, standard deviation; TIMI, thrombolysis in myocardial infarction.

Figure 4: Infarct Size by the Area Under the Curve of CK-MB and cTnT



CK-MB, creatine kinase-myocardial band; cTnT, cardiac troponin T; PCI, percutaneous coronary intervention.